Understanding participation habits among plaque psoriasis patients
Part of Skin clinical trials.
This study looks at why people with plaque psoriasis do or don't take part in clinical trials. It aims to learn more about participation habits to make future trials easier to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with plaque psoriasis.
- You must be at least 18 years old.
- You must be willing to follow the study rules and attend scheduled visits.
- You must agree to give written consent to take part.
- If you could become pregnant, you must have a negative pregnancy test and not be breastfeeding.
- You must not have any serious, unstable medical conditions (other than psoriasis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
This trial tests an oral medication called ICP-332 versus a placebo (a pill with no active drug) for people with moderate to severe plaque psoriasis. The goal is to see if ICP-332 can improve skin symptoms and be safe.
This study looks at how common fibromyalgia (a condition causing widespread pain and fatigue) is in people with plaque psoriasis. If you have plaque psoriasis, joining may help researchers understand the link between these two conditions.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.